Balertatug Biosimilar Monoclonal Antibody (CD70) for Research

Cat No.: GMP-Bios-INN-1093

Anti-CD70 therapeutic antibody (Pre-made Balertatug biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture,  assay development,  animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Balertatug (development codes PF-08046040/SGN-CD70) is a monoclonal antibody targeting CD70. It is developed by Seagen (Pfizer) for myeloid malignancies. It is in Phase I clinical development.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-INN-1093-1mg 1mg 3090
GMP-Bios-INN-1093-10mg 10mg
GMP-Bios-INN-1093-100mg 100mg
GMP-Bios-INN-1093-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Balertatug biosimilar, Whole mAb, Anti-CD70 Antibody: Anti-CD70/CD27-L/CD70 antigen/CD27 ligand (CD27-L) therapeutic antibody
INN Name Balertatug
Target CD70
Format Whole mAb
Derivation Humanized
Species Reactivity Human
CH1+2+3 Isotype G1
VD LC Kappa
Highest_Clin_Trial (Jan '20) TBC
Est. Status TBC
100% SI Structure None
99% SI Structure None
95-98% SI Structure None
Year Proposed 2025
Year Recommended na
Companies TBC
Conditions Approved TBC
Conditions Active TBC
Conditions Discontinued TBC
Production na
Development Tech TBC